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https://doi.org/10.1016/j.stemcr.2021.02.003SUMMARYApelin receptor (APLNR/AGTRLl1/APJ)marks a transient cell population during the differentiation of hematopoietic stem andprogenitor
cells (HSPCs) from pluripotent stem cells, but its function during the production and maintenance of hematopoietic stem cells is not
clear.We generated anAplnr-tdTomato reportermouse embryonic stem cell (mESC) line and showed thatHSPCs are generated exclusively
frommesodermal cells that express Aplnr-tdTomato. HSPC production frommESCs was impaired when Aplnrwas deleted, implying that
this pathway is required for their production. To address the role of APLNR signaling in HSPCmaintenance, we added APELIN ligands to
ex vivo AGM cultures. Activation of the APLNR pathway in this system impaired the generation of long-term reconstituting HSPCs and
appeared to drivemyeloid differentiation. Our data suggest that the APLNR signaling is required for the generation of cells that give rise to
HSCs, but that its subsequent downregulation is required for their maintenance.INTRODUCTION
Definitive hematopoietic stem and progenitor cells (HSPCs)
generate all cells of the blood and immune system, with the
most potent of these, the hematopoietic stem cell (HSC), be-
ing capable of repopulating the entire blood system upon
transplantation. HSPCs arise through a complex process,
precisely coordinated at a number of anatomical sites
throughout embryonic development. In the mouse embryo
the first wave of hematopoietic development originates in
the yolk sac around embryonic day 7.25 (E7.25) and gives
rise to primitive embryonic erythrocytes, megakaryocytes,
and macrophages (Palis, 2014). The second wave also origi-
nates from the yolk sac from E8.25 and gives rise to erythro-
myeloid progenitors that are defined by their ability to also
generate granulocytes andnatural killer cells (McGrath et al.,
2015; Dege et al., 2020). The third wave originates in the
ventral region of the developing dorsal aorta within the
aorta-gonad mesonephros (AGM) at E10.5–E11.5, where
HSCs, which can repopulate the entire hematopoietic sys-
tem upon transplantation, emerge (Medvinsky and Dzier-
zak, 1998; Medvinsky et al., 2008). HSCs arise from hemo-
genic endothelium through the progressive loss of
endothelial markers, such as VE-cadherin and gain of he-
matopoietic markers, such as CD41 and KIT (Dzierzak and
Medvinsky, 2008; Ivanovs et al., 2011; Medvinsky and
Dzierzak, 1996; Rybtsov et al., 2011; Taoudi andMedvinsky,
2007). HSCs have been visualized budding from intra-aortic
hematopoietic clusters before they are released into the cir-
culation (Bertrand et al., 2010; Boisset et al., 2010; KissaSte
This is an open access artiand Herbomel, 2010; Taoudi et al., 2005, 2008). Research
on the molecular mechanisms associated with the develop-
ment of HSPCs in the embryo has instructed the design of
culture protocols to model hematopoiesis in vitro from
pluripotent stemcells (PSCs) (Ivanovs et al., 2017). However,
it has proven challenging to generate bone fide HSCs that
are functionally capable of long-term reconstitution. The
small number of reports that claim to have succeeded, albeit
with very low efficiency, have done so by employing trans-
genic strategies and/or providing an in vivo environment
for their maturation (Ditadi et al., 2017; Sugimura et al.,
2017; Suzuki et al., 2013). It is unclear whether the failure
to detect transplantable HSCs from differentiating iPSCs re-
flects deficiencies in their generation or whether they are
produced but fail to be maintained. Our recent finding
that HS-like cells are generated transiently during human
iPSCdifferentiation indicates that theirmaintenance is a sig-
nificant problem (Fidanza et al., 2020). Further insight into
the cellular andmolecularmechanisms associatedwithboth
the production andmaintenance of HSCs in vivo and in vitro
will aid in designing improved culture conditions for the
efficient in vitro production of functional HSCs.
The Apelin receptor gene (Aplnr/Agtrl1/Apj) encodes a
member of the G protein-coupled receptor family and has
been implicated in cardiac, endothelial, and hematopoietic
development in a number of model systems (D’Aniello
et al., 2009; Inui et al., 2006; Quertermous, 2007; Scott
et al., 2007). Pertinent to this study is the involvement of
Aplnr Aplnr in endothelial cell maturation during develop-
ment and the fact that it appears to be expressed at a higherm Cell Reports j Vol. 16 j 1–14 j April 13, 2021 j ª 2021 The Author(s). 1
cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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could be related to their hemogenic potential both inmouse
(Kidoya et al., 2015; Kidoya et al., 2008, 2010) and human
embryos (Crosse et al., 2020). In the adult bone marrow,
endothelial cells that express APELIN, one of the APLNR li-
gands, participate in vascular remodeling after irradiation
and drive post-transplant recovery through feedback from
HSPCs (Chen et al., 2019). The expression profile of the
genes encodingAPELIN and its ligands (APELIN andAPELA)
during early mouse embryonic development indicates that
this signaling pathway is also active in the mesoderm and
its derivatives (D’Aniello et al., 2009; Devic et al., 1999). In
differentiating humanPSCsAPLNR is expressed inMixl1-ex-
pressing mesodermal progenitors, and the addition of APE-
LIN increased the production of blast colonies, which are
considered to be derived from a common precursor to endo-
thelial and hematopoietic cells (Yu et al., 2012; Vodyanik
et al., 2010). Our previous research has also implicated the
APLNR pathway during hematopoietic development
in vitro. We showed that the expression of genes encoding
APLNR and one of its ligands, APELIN, correlated with the
increased production of HSPCs when the transcription fac-
tor, HOXB4 was activated in differentiating mouse and hu-
man PSCs (Jackson et al., 2012, 2016). Although all of these
studies implicate a role for APLNR signaling during hemato-
poietic development, the specific function of this pathway
has not been addressed directly. To this end, we generated
an Aplnr-tdTomato reporter mouse ESC (mESC) line and
have shown that the Aplnr-tdTomato reporter marks a pop-
ulation of differentiatingmesoderm cells that has the poten-
tial to form hematopoietic and endothelial lineages. We
then generated an Aplnr-null mESC line and demonstrated
that HSPCs productionwas significantly impaired, implying
that this signaling pathway is indeed required for their gen-
eration. To assess the role of APLNR signaling in HSC matu-
ration and maintenance, we added APELIN ligands to AGM
explant cultures and observed a marked decrease in the
number of long-term reconstituting HSCs and an increase
in the differentiation of myeloid cells.RESULTS
Aplnr-tdTomato Reporter Marks Mesodermal Cells in
Differentiating ESCs
Todefine thephenotypeof cells expressing theAPLNRrecep-
tor during hematopoietic differentiation of ESCs we gener-
ated an Aplnr-tdTomato reporter mESC line using CRISPR-
Cas9-mediated genome editing (Figure 1A). mESCs were
transfected with the Aplnr targeting vector, Cas9 plasmid,
and specific gRNAs. Thirty-five G418-resistant colonies
were selected and 18 of these were screened by genomic
PCR and Southern blotting (Figure S1A). We confirmed2 Stem Cell Reports j Vol. 16 j 1–14 j April 13, 2021that the Aplnr-tdTomato reporter faithfully mimicked Aplnr
transcript expression by demonstrating the expression of
Aplnr transcripts in fluorescence-activated cell sorting
(FACS)-sorted tdTomato-positive, but not tdTomato-nega-
tive cells (Figure 1B). However, we noted that the expression
of the Aplnr-tdTomato reporter did not correlate with the
expression of a protein detected by a commercially available
a-APLNR antibody (Figure S2). Real-time PCR analyses of
FACS-sorted cells detected Aplnr transcripts in cells sorted
based on expression of the Aplnr-tdTomato reporter but not
a-APLNR antibody staining, suggesting that the a-APLNR
antibodywasbindingnon-specifically to thecell surface (Fig-
ures S2AandS2B).Thiswas supportedbydemonstrating that
the a-APLNR antibody detected a protein in 293T cells that
donot expressAplnr transcripts (Figure S2C).Wewere finally
convinced that this commercial antibodywasnot specific for
APLNR when we demonstrated that it detected a protein in
differentiating Aplnr-null ESCs (see below) (Figure S2D).
These findings emphasized the requirement of the Aplr-
tdTomato reporter mESC lines in defining the potential of
APLNR-expressing cells.
The timing of expression of the Aplnr-tdTomato reporter
duringmESCdifferentiationwas comparedwith the cell sur-
face expression of E-cadherin (ECAD), an epithelial marker
that is expressed at a high level in undifferentiated PSCs
but downregulated upon differentiation intomesoderm lin-
eages (Malaguti et al., 2013). Because the APLNR is first ex-
pressed in the developing mesoderm of the mouse embryo,
we predict a mutually exclusive expression pattern with
ECAD. As expected, we observed ECAD expression in undif-
ferentiated ESCs (day 0) and expression was gradually
reducedasdifferentiationprogressed (Figure1C). Incontrast,
the Aplnr-tdTomato reporter was not expressed in undiffer-
entiated cells, and expression increased during differentia-
tion. Aplnr-tdTomato-expressing cells were first detected at
day 3 of differentiation in both ECAD+ and ECAD cells,
but byday 5 virtually all theAplnr-tdTomato-expressing cells
were ECAD (Figure 1C). Thus, differentiating ESCs transi-
tion from ECAD+APLNR to ECAD+APLNR+ phenotype,
which then downregulate ECAD to become ECADAPLNR+.
The highest proportion (20%) of the intermediate, double-
positive cells was present around day 3.
To confirm that the Aplnr-tdTomato reporter is expressed
in the emerging multipotent mesoderm, we show that
most of the cells expressing a high level of Aplnr-tdTomato
at day 3 co-expressed high levels of FLK1 and that around
half of these also express PDGFRa (Figure 1D). As differen-
tiation progressed, Aplnr-tdTomato was observed in cells
expressing the endothelial cell markers (VE-cadherin and
FLK1), with the majority of VE-CAD+ and FLK1+ cells
expressing the reporter at day 4 (Figure 1E). Hematopoietic
cells expressing CD41 were first detected in this differenti-







Figure 1. Aplnr-tdTomato Reporter ESC Line Mimics the Activity of the Aplnr Locus during ESC Differentiation and Tracks a
Transient Mesoderm Cell Population
(A) CRISPR-Cas9 gene-editing strategy. Guide RNAs were designed to cut the genomic region of chromosome 2 immediately after the Aplnr
coding sequence. Schematic of targeting vector that was used to insert the tdTomato reporter gene at this site, followed by a T2A sequence
and NeoR cassette (not shown).
(B) Quantitative RT-PCR of Aplnr expression in undifferentiated Aplnr-tdTomato reporter ESCs (day 0 [D0]), unsorted differentiated day 6
(D6) cells and day 6 cells sorted into Aplnr-tdTomato-positive (+) and -negative () populations (n = 3). Error bars represent standard
deviation of data from three independent experiments.
(C) Representative flow cytometry plots of Aplnr-tdTomato and E-cadherin expression during differentiation from undifferentiated ESCs
(D0) to day 5 of differentiation.
(D) Flow cytometry of Aplnr-tdTomato ESCs at day 3 of differentiation stained with antibodies to FLK1 and PDGFRa and then analyzed after
gating on either APLNR negative or APLNR high.
(E) Representative flow cytometry plots of Aplnr-tdTomato together with CD41, VE-cadherin, or FLK1 during differentiation from days 1 to
6 of differentiation.
(F) Proportion of Aplnr-tdTomato-positive cells detected by flow cytometry in undifferentiated (D0) cells and during a 14 day time course
of differentiation. Error bars represent standard deviation of data from three independent experiments.
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all, the highest proportion (around 70%) of Aplnr-tdTo-
mato cells was observed at day 4 and this gradually
declined as differentiation proceeded (Figure 1F).
Hematopoietic Activity Is within the Cell Populations
that Express High Levels of the Aplnr-td-Tomato
Reporter
Aplnr-tdTomato mESCs were differentiated into embryoid
bodies (EBs) for 5 days, dissociated, and cells expressingdifferent levels of Aplnr-tdTomato were isolated by flow cy-
tometry (Figure S3). The differentiation potential of FACS-
sorted cellswas assessedusingCFU-Cassays (Figure 2A).He-
matopoietic activitywas foundalmost exclusivelywithin in
the Aplnr-tdTomato-expressing cell population with virtu-
ally no CFU-Cs generated from the sorted Aplnr-tdTo-
mato-negative cell population. There was a significantly
higher overall number of CFU-Cs generated from cells ex-
pressing ahigh level ofAplnr-tdTomato comparedwith cells




Figure 2. Aplnr-tdTomato Marks Mesoderm Fated to Become Hemogenic Endothelium
(A) Number of CFU-Cs generated from 105 unsorted differentiating ESCs (day 6) and cell populations sorted biased a high (Hi), low (Lo), or
negligible (Neg) level of tdTomato expression (n = 3; *p < 0.05). Statistically significant difference in number of CFU-Mix (**p = 0.003) and
CFU-GM (*p < 0.03) colonies from Aplnr-tdTomato high and low cells. No difference was observed in the number of uni-lineage BFU-E and
CFU-M (see Figure S3 for FACS sorting strategy).
(B) Representative flow cytometry plots of differentiating Aplnr-tdTomato ESCs (day 6) co-stained with antibodies against KIT, TIE2, VE-
CAD, FLK1, and CD41. Backgating of cells expressing high, low, or negligible (Neg) levels of Aplnr-tdTomato demonstrates that cells
expressing TIE2, FLK1, VE-CAD (VC), KIT, and CD41 are primarily found in the Aplnr-tdTomato-high cell population.
(C) Quantification of flow cytometry data in (B) showing the percentage of cell type within each of the subpopulations defined by the level
of Aplnr-tdTomato expression (n = 3; *p < 0.05).
(D) Immunohistochemistry using an aCD31 antibody of differentiating ESCs after FACS and culturing on OP9 stromal cells in the presence
of VEGF, demonstrating the endothelial potential differentiating cells expressing high and low levels of Aplnr-tdTomato. Two replicate
experiments are shown. Scale bar represents 100 mm (340 magnification).
(E) Percentage of embryoid bodies (EBs) with associated beating cardiomyocytes in EBs generated from unsorted day 6 differentiating ESCs
or cells at this stage that were sorted based on the expression of high (Hi), low (Lo), or negligible (Neg) levels of Aplnr-tdTomato
expression.
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and CFU-GM colonies was significantly higher from cells
expressing a high level of Aplnr-tdTomato compared with
the cells expressing a low level of Aplnr-tdTomato, whereas
there was no significant difference in the production of sin-
gle lineage colonies (Figure 2A).
Backgating of cells expressing high, low, or negligible
(Neg) levels of Aplnr-tdTomato demonstrated that cells ex-4 Stem Cell Reports j Vol. 16 j 1–14 j April 13, 2021pressing TIE2, FLK1, VE-CAD (VC), KIT, and CD41 are pri-
marily found in the Aplnr-tdTomato-high cell population
(Figure 2B). A subset of these cells also expressed the he-
matopoietic markers CD41 and KIT, implying that APLNR
is expressed at the transitional state from an endothelial
to hematopoietic phenotype (Figures 2B and 2C).
Aplnr-tdTomato-expressing cells were plated onto irradi-
ated OP9 cells, cultured in the presence of VEGF for
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marker, CD31, to assess their potential to form endothelial
cells (Figure 2D). Cells expressing high and low levels of
Aplnr-tdTomato generated endothelial structures consist-
ing of CD31+ cells but no such structures were produced
by Aplnr-tdTomato-negative cells. To assess whether the
Aplnr-tdTomato reporter was marking all mesoderm pro-
genitors or a subpopulation committed to hematopoietic
and endothelial lineages, we assessed the potential of
sorted cells to differentiated into another mesodermal cell
type. EBs were dissociated at day 6, sorted based on the
expression of Aplnr-tdTomato, and then assessed for their
potential to generate cells of the cardiac lineage. Although
sorting reduced the overall production of beating cardio-
myocytes compared with unsorted cells, there was no cor-
relation between the level of Aplnr-tdTomato expression
and the potential to generate cardiac cells suggesting that
cardiomyocytes could be generated from mesoderm that
did not expressAplnr-tdTomato (Figure 2E). Taken together,
these data support our hypothesis that the Aplnr-tdTomato
reporter marks mesoderm and that Aplnr expression is spe-
cifically required for the efficient endothelial and hemato-
poietic differentiation.
Aplnr Is Required for Hematopoietic Cell Production
from ESCs
To confirm that APLNR signaling is required during the dif-
ferentiation of hematopoietic cells from PSCs, we gener-
ated Aplnr-null mESCs using a CRISPR-Cas9 strategy. Aplnr
is a single-exon transcript with a coding region of 1,131
base pairs (bp), so our strategy involved excising the com-
plete coding region using guide RNAs directed to the 50
and 30 ends (Figure S4A). pSPCas9-2A-mCherry-U6-gRNA
plasmids containing pre-selected gRNAs (see the Experi-
mental Procedures) were transfected into E14 mESCs. Cells
that had been successfully transfected were sorted based on
mCherry expression 24–48 h after transfection and then
plated at low density. Individual mESC clones were isolated
and genomic DNAwas screened by PCR using primers that
spanned the deleted region. The PCR assay was designed to
amplify a 589 bp product from the deleted, knockout (KO)
allele and a 1,700 bp amplicon from the wild-type (WT)
allele. The KO allele was identified in 7 out of 30
mCherry-positive clones (Figure S4B). This assay did not
distinguish between heterozygous and homozygous clones
because the smaller 589 bp amplicon associated with the
KO allele would likely be amplified preferentially over the
larger WT allele. To differentiate between functionally het-
erozygous and homozygous mESC clones, we sequenced
the amplicons and found that, in the majority of clones
that had one deleted Aplnr allele, the second Aplnr allele
had an insertion or a deletion that resulted in a frameshift
mutation (data not shown). Quantitative real-time PCRwas used to select clones in which the targeting events re-
sulted in ablation of Aplnr transcripts and could therefore
be considered as functionally null at the Aplnr locus
(Figure S4C).
Aplnr-null mESCs could be maintained as undifferenti-
ated ESCs in the presence of leukemia inhibitory factor
(LIF) in a comparable manner with controls (data not
shown). However, when induced to differentiate and as-
sessed in hematopoietic colony assays, significantly lower
numbers of hematopoietic CFU-C colonies (CFU-M, CFU-
GM, and CFU-Mix) were formed from two independently
derived Aplnr-null ESCs compared with control WT ESCs
at day 6 of differentiation (Figure 3A). Flow cytometry ana-
lyses confirmed that the Aplnr-null ESCs produced a lower
proportion of CD41+VE-cadherin+ hematopoietic progeni-
tor cells (HPCs) (Figures 3B and 3C).
When subjected to amacrophage-specific differentiation
protocol, the proportion of mature F4/80+CD11B+CD16+
macrophages generated from Aplnr-null ESCs was signifi-
cantly lower than controls (Figure 3D). To confirm that
the reduced hematopoietic differentiation was due to the
absence of Aplnr and not simply a consequence of ESC
clonal variation, we introduced an APLNR-expressing
plasmid into the Aplnr-null ESC clones and demonstrated
that the production of F4/80+CD11b+ macrophages was
increased in the presence of the exogenous Aplnr (Fig-
ure 3D). These data indicate that the APLNR pathway is
required for the development of HPCs and for the differen-
tiation of the myeloid lineage.
Activation of the APLNR Pathway Has No Significant
Effect on the Production ofHematopoietic Progenitors
in Differentiating Mouse and Human PSCs
As HSPC production is impaired when Aplnr is deleted, we
hypothesized that their production might be increased
when the APLNR pathway is activated by known APLNR li-
gands, such as APELIN. However, when APELIN was added
to the serum-free cytokine-based hematopoietic differenti-
ation of mESCs, we observed no effect on the number or
phenotype of CFU-Cs (Figure 4A). This was somewhat un-
expected given that previous studies had reported promo-
tion of the production of blast colonies when Apelin was
added to differentiating human ESCs (Yu et al., 2012). To
confirm that the effects we had observed were not species
specific we replicated our findings using both human
ESCs and induced pluripotent stem cells (iPSCs), again
demonstrating that the addition of APELIN peptides had
no effect on CFU-C formation (Figure 4B). This apparent
discrepancy might be partly explained by the fact that
two of the proposed ligands (APELIN and APELA) for
APLNR are expressed in differentiating ESCs (Figure S5).
This could suggest that the APLNR signaling pathway is
already activated and that any further addition of ligandStem Cell Reports j Vol. 16 j 1–14 j April 13, 2021 5
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Figure 3. Targeted Deletion of Aplnr Results in Impaired Hematopoietic Differentiation
(A) Number of hematopoietic CFU-C colonies generated from 105 differentiated (day 6) control ESCs and two independently derived Aplnr-
null (Null1 and Null2) ESC clones. CFU-M (macrophage), CFU-GM (granulocye/macrophage), CFU-GEMM (multilineage, including gran-
ulocyte, erythroid, macrophage, and megakaryocytes), 20 EB-ery (secondary embryoid bodies with associated erythroid cells) (*p < 0.05).
Error bars represent standard deviation of data from four independent experiments.
(B) Representative flow cytometry analyses of day 6 differentiated control ESCs and two independently derived Aplnr-null ESC clones (Null1
and Null2) using antibodies to VE-CAD and CD41.
(C) Quantification of flow cytometry analyses (B) showing the percentage of VE-CAD+CD41+ cells at day 6 of differentiation from control
and two Aplnr-null ESC clones (*p < 0.05). Error bars represent standard deviation of data from three independent experiments.
(D) Representative flow cytometry of cells generated following the macrophage differentiation protocol of control (wild type), two Aplnr-
null ESC lines (Null1 and Null2), and the Null1 and Null2 ESCs that were transfected with an APLNR-expressing plasmid (+APLNR).
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when APELIN ligands were included in the CFU-C assay, an
increase in macrophage colonies was observed, implying
that activation of the pathway might drive the differentia-
tion of HPCs into myeloid lineages (Figure S6).
Genes expressing APLNR and Its Ligands Are
Expressed at the Site of HSC Emergence In Vivo
To assess the role of the APLNR pathway in HSPC mainte-
nance and differentiation, we turned to the mouse AGM
explant system that is known to support both the matura-
tion and maintenance of definitive HSPCs (Taoudi et al.,
2008). We first demonstrated that the genes encoding
APLNR and its ligands, APELIN and APELA, were expressed
in the region of the developing embryo at E9.5 and E11.5
when definitive HSCs first emerge (Figure 5A). Low, but
detectable levels of expression were also observed in the
yolk sac and fetal liver. These data support the hypothesis
that the APLNR signaling pathway is active during the emer-
gence of HSCs in vivo. To further define which cell types
within the AGM express the genes encoding APLNR and its
ligands we analyzed published datasets from single-cell6 Stem Cell Reports j Vol. 16 j 1–14 j April 13, 2021RNA sequencing of mouse AGM tissue (GEO: GSE143637)
(Vink et al., 2020), human AGM tissue (GEO: GSE151877;
sample GSM4592621) (Crosse et al., 2020) and differenti-
ating human iPSCs (Database: EMBL EBI Arrayexpress;
E-MTAB-9295 (Fidanza et al., 2020). Aplnr/APLNR is ex-
pressedat a relativelyhigh level inmostof thecells associated
with endothelial cell clusters in both mouse and human
AGM and in differentiating human iPSCs (Figures 5B–5D).
RNA encoding the ligand APELIN was expressed in more
restricted subpopulations of endothelial cells in all datasets,
whereas RNA encodingAPELAwas barely detectable (Figures
5B–5D). Interestingly, within HSPC clusters, RNA encoding
APLNR and APELIN (but not APELA) was detected inmouse
butnothumanAGMtissue.APLNR transcriptsweredetected
in some iPSC-derived HSPCs, supporting the idea that
APLNR could be expressed in cells at the EHT transition.
Activation of the APLNR Pathway Reduces the
Production of Transplantable HSCs in Aggregate
Cultures
To assess whether activation of the APLNR pathway could
influence the production, maintenance, or differentiation
A B
Figure 4. Addition of APELIN Ligands to Differentiating Mouse and Human PSCs Does Not Enhance Hematopoietic Colony Pro-
duction
(A) Number of CFU-Cs generated in differentiating mESCs with no APELIN ligands added (control) and after the addition of APELIN 13 (A13)
or APELIN 36 (A36) at 30 and 100 nM (n = 3).
(B) Number of CFU-Cs generated in differentiating human ESCs (H1) (n = 8) and human iPSCs (SFCi55) (n = 3) in control cultures with no
APELIN ligands added (no A) and after the addition of APELIN 13 (A13) or APELIN 36 (A36). Error bars represent standard deviation of data
from three independent experiments (A and B).
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36 (A36), or APELA 21 (A21), which are known to support
ex vivo maturation and expansion of definitive HSCs, to
AGM reaggregation cultures (Figure 6A) (Rybtsov et al.,
2014; Taoudi et al., 2008). The caudal region of E9.5 em-
bryos that includes AGM tissue was dissected and placed
in the aggregation culture in the presence of cytokines,
with or without Apelin peptides, for 7 days. Resultant
cells were assessed for CFU-C formation, flow cytometry,
and their ability to reconstitute lethally irradiated recipi-
ents in vivo. The addition of either A13 or A36 peptides
to the aggregate cultures resulted in a slight, but not
significant, increase in the total number of hematopoietic
progenitors as assessed by CFU-C production (Figure 6B).
Flow cytometry analyses of cells derived from the CFU-C
colonies demonstrated an increase in the proportion of
mature myeloid cells expressing high levels of CD11b, a
proportion of which also expressed Gr1 (Figures 6C and
6D). The increase in the production of mature myeloid
cells in the presence of APLNR ligands coincided with a
decrease in the production of immature (LIN/SCA+/
KIT+) HPCs (Figure 6E).
To assess the effects of APLNR ligands on the produc-
tion of functional reconstituting HSCs in ex vivo cultures,
day 9.5 AGM cells (CD45.2) were cultured for 7 days in
the presence of various concentrations of A13, A36, or
A21, and then resultant cells were transplanted into irra-
diated CD45.1/2 recipients. Almost all (8/9) recipients
that received control cell aggregates cultured without
Apelin peptides demonstrated successful HSC reconstitu-
tion at 14 weeks after transplantation (>10% CD45+). Incontrast, when a high concentration (300 nM) of A13,
A36, or A21 was added to the aggregate culture, the num-
ber of successfully transplanted animals was reduced to
3/6, 1/10, and 2/6, respectively (Figure 5G). The effect
of peptide addition was dose dependent, with the addi-
tion of a lower concentration (100 nM) of all peptides
having a less profound detrimental effect on the ability
of cultured cells to reconstitute the hematopoietic
system of irradiated recipient mice (Figure 5G). To define
the timing of this detrimental effect, we isolated pre-HSC
type I (VC+CD41loCD43+CD45) and pre-HSC type II
cells (VC+CD41loCD43+CD45+) from day 11.5 AGM tis-
sue and assessed the effect of A36 on their subsequent
maturation into functional HSCs within aggregate cul-
tures (Figure 5H). In control cultures, pre-HSC type I
could be matured ex vivo into reconstituting HSCs, but
in the presence of APELIN 36 resultant cells did not
reconstitute irradiated mice. A comparable, but less pro-
found effect of A36 was observed on pre-HSC type II
when again reconstitution was significantly reduced.
These data demonstrate that activation of the APLNR
pathway by the addition of ligands is detrimental to
the generation and maintenance of functional HSCs in
ex vivo cultures.
Taken together, the results of our study indicate
that the APLNR pathway is required for the production
of hematopoietic cells but that the activation of the
APLNR pathway at a later stage negatively affects HSC
function. The increased production of myeloid cells in
the presence of APLNR ligands both in explant cultures
and in differentiating human ESCs suggests that thisStem Cell Reports j Vol. 16 j 1–14 j April 13, 2021 7
A
B C D
Figure 5. Expression of Aplnr, Apelin, and Apela in Hematopoietic Tissue
(A) Quantitative RT-PCR analyses of RNA isolated from the AGM region, yolk sac (YS), and fetal liver (FL) dissected from embryos at the
indicated stage of development using primers to detect transcripts encoding APLNR and its ligands, APELIN and APELA (n = 2).
(B–D) UMAP plots of single-cell sequencing data derived from mouse (B) and human (C) AGM tissue and differentiating human iPSCs (D)
demonstrating Aplnr/APLNR, Apelin/APELIN, and Apela/APELA expression in endothelial cell clusters. Endothelial cell and HSPC clusters
are highlighted with solid and dotted outlines, respectively.
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renewal.DISCUSSION
We previously identified the genes encoding APLNR and
its ligand APELIN as the most highly upregulated genes
when HOXB4 was activated in differentiating mESCs
(Jackson et al., 2012). As this increase in expression
correlated with an enhanced hematopoietic differentia-
tion, we hypothesized that the APLNR signaling pathway
could be associated with the production and/or mainte-
nance of HSPCs. Here, we show that the Aplnr-tdTomato
reporter marks differentiating mesodermal cells that8 Stem Cell Reports j Vol. 16 j 1–14 j April 13, 2021have the potential to differentiate into hematopoietic
and endothelial lineages and that deletion of the Aplnr
gene impairs the in vitro production of HSPCs from
mESCs. Our findings are consistent with previous studies
that have reported a role for this signaling pathway in
mesoderm progenitors in both mouse and human differ-
entiating ESCs (Yu et al., 2012; Vodyanik et al., 2010;
D’Aniello et al., 2013).
We show that the cells expressing the highest level of the
Aplnr-tdTomato reporter also express the highest level of
endothelial markers. Our analyses of single-cell sequence
data from mouse and human AGM tissue and differenti-
ating iPSCs further confirmed Aplnr/APLNR expression in
endothelial cells.We noted that a proportion ofAplnr-tdTo-





Figure 6. Addition of Aplnr Ligands to AGM Reaggregate Explant Cultures Results in a Reduction in Transplantable HSCs
(A) Schematic of experimental strategy for E9.5 dissection (as example) where the caudal region of the embryo was dissected, tissue
dissociated, set up in reaggregate cultures in the presence of Apelin peptides for 7 days and then assayed by for colony formation (CFU-C),
flow cytometry, and transplantation into lethally irradiated mice.
(B) CFU-C analyses of reaggregate cultures in the absence (0) or presence (100 or 300 nM) of APELIN 13, APELIN 36, or APELA 21. Error bars
represent standard deviation of data from three independent experiments.
(C) Representative flow cytometry plots of live cells obtained after 7 days of E9.5 aggregate culture in presence of APELIN 13, APELIN 36, or
APELA 21 using antibodies against the myeloid markers, CD11B and GR1).
(D) Quantification of flow cytometry in (C).
(legend continued on next page)
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This is in keeping with single-cell sequencing analyses of
human AGM implying thatAPLNRwas expressed in hemo-
genic endothelium (Crosse et al., 2020). Two further
studies have reported the downregulation of Aplnr as endo-
thelial cells acquire hematopoietic markers during EHT
(Bruveris et al., 2020; Oatley et al., 2020). The slight differ-
ence in the timing of Aplnr downregulation in cells that
have acquired hematopoietic markers that we report might
reflect the slightly longer half-life of tdTomato compared
with Aplnr transcripts.
We observed no change in the numbers or phenotype of
CFU-C formation after the addition of APELIN ligands to
mouse or human ESCs and iPSCs, whereas a previous study
reported that Apelin promoted hematopoietic differentia-
tion of human ESCs (Yu et al., 2012). We believe that this
apparent discrepancy actually highlights the importance
APLNR signaling at the transitional state between endothe-
lial and hematopoietic fate because the positive effect of
APELIN on hematopoietic differentiation of human ESCs
was reflected in an increase in the number of bipotential
blast colonies (Yu et al., 2012). We have shown that tran-
scripts encoding APELIN ligands are present within differ-
entiating mouse and human ESC/iPSC cultures, and it is
possible that this would mask the effects of exogenous
ligand addition.
In AGM explant reaggregation cultures we show that
addition of APLNR ligands results in a reduction in HSCs
capable of long-term reconstitution and a concomitant in-
crease in the production ofmorematuremyeloid cells. This
finding suggests that activation of the APLNR pathway is
detrimental to the maintenance of HSCs and provides the
first indication that the precise modulation of APLNR
signaling is critical in steady-state hematopoiesis. The in-
crease in the production ofmyeloid cells by APELIN ligands
in ex vivo cultures is consistent with our observation that
the in vitro production of macrophages from ESCs is signif-
icantly impaired in the absence of APLNR and that the
addition of APELIN to the CFU-C assay resulted in an in-
crease in macrophage colony formation. In future it would
be interesting to assess whether the addition of APLNR li-
gands affects cell cycle, the speed of which has been shown
to be important for the emergence of functional definitive
HSCs within the hematopoietic clusters the AGM region
(Batsivari et al., 2017).(E) Proportion of LINSCA+KIT+ HPCs after 7 days of E9.5 aggregate cul
(F) Proportion of CD45.2 donor cells present in the peripheral blood of
derived from E9 ex vivo reaggregate cultures in the absence (0) or prese
point represents one recipient animal.
(G) Proportion of CD45.2 donor cells present in the peripheral blood
aggregate cultures that consisted of sorted pre-HSC type I and type II
presence of 100 or 300 nM APELIN 13 or APELIN 36.
10 Stem Cell Reports j Vol. 16 j 1–14 j April 13, 2021The differential requirements for APLNR signaling at pre-
cise stages of HSC emergence andmaintenance is compara-
ble with that reported for other signaling pathways, such as
the NOTCH signaling pathway, where stage-specific effects
are observed in the production of adult HSCs in vivo (Souil-
hol et al., 2016) and in HSPC production in vitro from ESCs
(Huang et al., 2013).
Critical to the interpretation and the relevance of our
findings to hematopoietic development and maintenance
in vivo is the anatomical and temporal expression of APLNR
ligands. Pertinent to this point is the finding, using Apln-
CreER Rosa26-mTmG reporter mice, that APELIN is ex-
pressed in a subpopulation of endothelial cells in adult
bone. Conditional knockout of this endothelial cell popu-
lation revealed their critical role in hematopoietic regener-
ation following myeloablation (Chen et al., 2019). It is not
clear which of the ligands are important in the activation of
APLNR in different cell types and it is not known which of
the many downstream intracellular pathways are respon-
sible for exerting the ultimate biological effects. A condi-
tional knockout approach for the APLNR receptor and
the production of mice carrying the Aplnr-tdTomato re-
porter will be instrumental in gaining a fuller understand-
ing the complexity of this pathway during hematopoietic
development and maintenance in vivo.EXPERIMENTAL PROCEDURES
mESC Maintenance and Differentiation
ThemESC line E14IVwasmaintained inGlasgowMinimumEssen-
tialMedium (Gibco) supplementedwith 10% fetal calf serum (FCS)
(Lonza), 2 mM sodium pyruvate (Gibco), 4 mM L-glutamine
(Gibco), 1%non-essential amino acids (Gibco), and 0.1mM b-mer-
captoethanol (Sigma) and 100 U/mL of LIF, as described previously
(Jackson et al., 2012).
Hematopoietic Differentiation of mESCs
Two days before differentiation, mESCs were plated in N2B27 me-
dium supplemented with 100 U/mL LIF and 10 ng/mL BMP4 to
allow cells to adjust to serum-free conditions. To initiate differen-
tiation, at day 0 cells were disaggregated with Accutase (Gibco)
then resuspended in N2B27 containing 2.5 ng/mL Activin A,
10 ng/mL basic-helix-loop-helix (bFGF), and 5 ng/mL BMP4 and
plated in ultra-low attachment plates (STEMCELL Technologies).
Two days later, EBs were plated on gelatinized tissue culture plates
in N2B27 containing 10 ng/mL bFGF, 5 ng/mL BMP4, and 15 ng/ture in the presence of APELIN 13, APELIN 36, or APELA 21 peptides.
lethally irradiated recipients 14 weeks after transplantation of cells
nce of 100 or 300 nM APELIN 13, APELIN 36, or APELA 21. Each data
of lethally irradiated recipients 14 weeks after transplantation of
cells derived from E11 in coaggregate cultures in the absence (0) or
Please cite this article in press as: Jackson et al., Modulation of APLNR Signaling Is Required during the Development and Maintenance of
the Hematopoietic System, Stem Cell Reports (2021), https://doi.org/10.1016/j.stemcr.2021.02.003mLVEGF for 6 days, with a medium change on day 4. At day 6 the
cells were harvested using Accutase (Gibco), counted, and single-
cell suspensions were stained with antibodies for flow cytometry
and/or plated in CFU-C assays that were scored 10 days later.
In experiments to assess the effects of activating the APLNR
pathway, APELIN peptides were added from day 0, specifically,
APELIN36(LVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF),
its cleaved bioactive pyroglutamyl form (Pyr1), APELIN 13
(QRPRLSHKGPMPF), and APELA 21 (LYRHACPRRRCIPLHSRVPFP)
(Phoenix Pharmaceuticals). Macrophage differentiation was car-
ried out as described previously (Haideri et al., 2017).Human ESC and iPSC Differentiation
Human ESCs and human iPSCs weremaintained on CELLstart (In-
vitrogen)-coated 6-well tissue culture plates (Costar) in StemPro
medium comprising DMEM/F12 with GlutaMAX (Invitrogen),
1.8% BSA (Invitrogen), StemPro supplement (Invitrogen),
0.1 mM b-mercaptoethanol (Invitrogen), and 20 ng/mL human
bFGF (Invitrogen), as described previously (Jackson et al., 2016;
Yang et al., 2017). Cells were passaged mechanically when they
reached about 80% confluency using the EZPassage tool (Invitro-
gen). In experiments to assess the effects of activating the APLNR
pathway, APELIN peptides were added from day 0. The use of hu-
man ESCs in haematopoietic differentiation experiments was
approved by UK Stem Cell Bank.Generation of Aplnr-tdTomato Reporter ESC Lines
AplnrT2ATdTomato HDR donor vector was based on the backbone
pBSK-2A-iCre-frtneofrt (a gift from Heiko Lickert), which was di-
gested with Not1 and EcoR1 to accept two overlapping PCR frag-
ments and a 1 kb 30 arm by Gibson assembly (NEB).
Aplnr (NM 011784.3) is a single-exon gene and so the coding re-
gion of approximately 1 kb acted as the 50 homology arm. A PCR
fragment consisting of theAplnr coding region and the T2A-encod-
ing sequence was generated by amplification of BAC
BMQ407G118 using primers overlapping the backbone at the 50
end and introducing the T2A sequence at the 30 end. The T2ATdTo-
mato sequence was generated by PCR of pTdTomato (Clontech).
The integrity of the vector was tested by sub-cloning the entire
expression cassette into CAG-IRES-Puro vector and the tdTomato
signal confirmed in transient transfected ESCs by flow cytometry.
Guide RNAs (gRNA) directed to the 30 end of the Aplnr sequence
were predicted by the Zhang lab algorithm (https://zlab.bio).
gRNAs directed to the sequence 30 to the Aplnr stop codon were
identified and tested functionally using the SplitAx assay (Axton
et al., 2017). In brief, a SplitAx vector consisting of the sequence
encoding the N-terminal of GFP, the Aplnr sequence that covered
the region that the gRNAs were directed to, and the sequence en-
coding the C-terminal of GFP that was out of frame with the N-ter-
minal sequence. After transfection of this SplitAx vector and
gRNAs into HEK293 cells, gRNAs were selected if they successfully
cut the SplitAx vector and resulted in reconstitution of an in-frame
GFP. Transfection of gRNA A2 (TGGGTCAGACCCGCTGCACC)
binding to CCTGGTGCAGCGGGTCTGACCCA and gRNA B2
(GGAGAAAGTACAGCCATGCT) binding to AGCATGGCTG-
TACTTTCTCC resulted in a positive GFP signal in the SplitAx assay
andwere used for the subsequent gene targeting. Guides A2 and B2were cloned into TOPO blunt after a synthesized U6 promoter
(IDT) before sub-cloning into the guide vector, pGL3-U6-sgRNA
EGFP (Liu et al., 2018).
Juo9 (subclone of E14)murine ESCs (23 106) were transfected in
suspension with 3 mg AplnrT2ATdTomato HDR donor vector, 1 mg
gRNA-A2 plasmid, 1 mgRNA-B2 plasmid, and 1 mg Cas9 Nicka-
se(D10A)-GFP plasmid (Addgene no. 48140) or Hu Cas9-GFP
(Addgene no. 44720) using Xfect stem transfection reagent (Clon-
tech) in 100 mL Xfect buffer and 2 mL Xfect polymer for 4 h. mESC
medium was added to a volume of 2 mL and plated out overnight
in gelatinized 6-well plates. Following overnight incubation,
40,000 GFP+ cells were FACS sorted and plated in a gelatinized
10 cm plate. G418 selection (400 mg/mL) was added the next day
and, after 7 days, 28 G418-resistant colonies from the Cas9 D10A
transfections and 80 colonies from the WT Cas9 transfections
were generated. Thirty-fve colonies were picked and screened by
PCR for correctly targeted 30 and 50 ends, which were then
confirmed by Southern blot.
Generation of Aplnr-Null ESC Lines
gRNA sequences were identified (http://www.sanger.ac.uk/htgt/
wge/find_crisprs). Four gRNAs with PAM sites after the ATG that
had a low number of predicted off target binding sites and two
guides with the PAM site after the TAA stop codon were selected.
Linker nucleotides were added to the ends of the gRNA sequences
and both strands synthesized (IDT). gRNAs were annealed and
then ligated into the Bbs1 site of linearized pSPCAs9(Guide)-2A-
mCherry vector. Combinations of 50 and 30 gRNAs were tested by
transient transfection of mESCs and screened for excision of the
coding region by PCR. Combinations with the highest level of
excision in these transient transfections were used to generate
clonal Aplnr-null ESC. ESCs (1 3 106 3 1014) were transfected
with the two appropriate pSPCAs9(Guide)-2A-mCherry vectors us-
ingXfect (Clontech). Forty-eight hours after transfection cells were
sorted for high levels of mCherry expression and plated onto
10 cm gelatinized dishes. Ten days later individual colonies were
picked and screened using primers that spanned the coding region.
Animals
Staged embryos were obtained by mating C57BL/6 (CD45.2/2),
and the morning of discovery of the vaginal plug was designated
as day 0.5. For culture and transplantation, embryonic day 9.5
(E9.5) (25–29 sp) and E11.0–E11.5 (>40 sp) samples were used.
All experiments with animals were performed under a Project Li-
cense granted by the Home Office (UK), University of Edinburgh
Ethical Review Committee, and conducted in accordance with
local guidelines.
Long-Term Repopulation Assay and Blood Chimerism
Analysis
CD45.2/2 cells were injected into irradiated 2- to 3-month-old Bl/
6J CD45.1/2 heterozygous recipients along with 100,000 CD45.1/
1 nucleated bone marrow carrier cells per recipient. Recipients
were g-irradiated using two doses (600 + 550 rad) separated by 3
h. For day 9.5 culture, one embryo equivalent (e.e.) of the 7 day
cultured cells was injected. E11 AGM-sorted cells were injected af-
ter 5 days of OP9-coaggregate culture at a dose of 1 e.e./recipient.Stem Cell Reports j Vol. 16 j 1–14 j April 13, 2021 11
Please cite this article in press as: Jackson et al., Modulation of APLNR Signaling Is Required during the Development and Maintenance of
the Hematopoietic System, Stem Cell Reports (2021), https://doi.org/10.1016/j.stemcr.2021.02.003Donor-derived chimerism was evaluated in peripheral blood at 6
and 14 weeks post transplantation. Erythrocytes were lysed using
Pharm Lyse (BD Biosciences), and non-specific binding was
blocked with an anti-CD16/32 (Fc-block) followed by staining
with anti-CD45.1-APC (clone A20) and anti-CD45.2-PE (clone
104) monoclonal antibodies (eBioscience). Cell populations were
identified as CD45.1-PE+ (donor), CD45.1-PE+CD45.2-APC+
(recipient), CD45.1-APC+ (carrier) using FACSCalibur or Fortessa
(BD Biosciences).
HSC numbers were assessed using extreme limiting dilution
analysis (ELDA) analysis (Hu and Smyth, 2009). Multilineage
donor-derived hematopoietic contribution in recipient blood
and organs was determined by staining with anti-CD45.1-V450,
anti-CD45.2-V500, and lineage-specific anti-Mac1-fluorescein iso-
thiocyanate (FITC), Gr1-PE CD3e-APC, B220-PE-Cy7 monoclonal
antibodies (BD Pharmingen).Ex Vivo Maturation of HSC Precursors
E9.5 and E11.5 embryos were dissected as described (Rybtsov et al.,
2014). Tissues were incubated with collagenase/dispase solution
(0.12 mg/mL) (Roche) at 37C as described (Taoudi et al., 2008),
washed, and resuspended in PBS (Sigma) containing 3% FCS and
then dissociated by pipetting. After dissociation (and sorting) 1
e.e. of the specific cell populations (e.g., type I or type II pre-
HSCs) were coaggregated with 105 OP9 cells. Five to ten coaggre-
gates (i.e., 5–10 e.e.) per experimental variant were cultured in Is-
cove’s modified Dulbecco’s medium (Invitrogen), with 20% of
pre-selected, heat-inactivated FCS, L-glutamine, and penicillin/
streptomycin supplemented with murine recombinant cytokines
(SCF, IL3, and Flt3) each at 100 ng/mL (PeproTech) and various
concentrations of APLNR ligand peptides, including APELIN
36 (LVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF), its
cleaved bioactive pyroglutamyl form (Pyr1) APELIN 13
(QRPRLSHKGPMPF), and APELA 21 (LYRHACPRRRCIPLHSRVPFP)
(Phoenix Pharmaceuticals). Coaggregates were cultured on
floating 0.8 mm AAWP 25 mm nitrocellulose membranes (Milli-
pore) for 6 days then dissociated using collagenase/dispase as
described (Rybtsov et al., 2014).CFU-C and Endothelial Assays
A methylcellulose-based hematopoietic progenitor assay was
routinely used to enumerate hematopoietic progenitors from
both mouse (MethoCult GF M3434, STEMCELL Technologies)
and human (MethoCult H4434, STEMCELL Technologies) differ-
entiating PSC. Cells were collected from the differentiating PSC
culture and prepared in single-cell suspensions. Methylcellulose
medium (1.5 mL) was added into a 35 mm low attachment
dish. For each cell treatment, two dishes were set up in parallel
at densities of 1 3 105 and 5 3 104 for mouse cells and at 1 3
104 and 5 3 103 for human cells, then incubated at 37C, and
then scored between 7–11 and 12–14 days for mouse and human
cells, respectively. Colonies were classified based on the
morphology using light microscopy. For endothelial assays, cell
was placed on an OP9 cell layer in the presence of 50 ng/mL
VEGF as described (Rybtsov et al., 2014). After 11 days, cultures
were stained with anti-CD31 antibodies to assess endothelial
colonies.12 Stem Cell Reports j Vol. 16 j 1–14 j April 13, 2021FACS and Analysis
Cell suspensions were stained with following antibodies: Ter119-
v500 clone (Clone TER-119); anti-CD41-BV421 (brilliant violet
421) or Alexa Fluor 488 (clone MW30reg); anti-CD45 FITC (clone
30-F11); biotinylated anti-VE-cadherin (clone 11.D4.1) followed
by incubation with streptavidin-APC (all purchased from BD
Pharmingen or BioLegend). Anti-mouse VE-cadherin (VC) anti-
body was biotinylated in-house using the FluoReporter Mini-
Biotin-XX Protein Labeling Kit (Invitrogen). Cell populations
were sorted using a FACSAria II sorter (BD) followed by purity
checks. Type I pre-HSCs (Ter119VC+CD41+CD45-) and type II
pre-HSCs (Ter119VC+CD41+CD45+) were sorted from E11
AGMs as described previously (Rybtsov et al., 2011). Dead cells
were excluded using 7AAD staining and fluorescence minus one
control staining was used to define gating strategies. Data acqui-
sition and analyses were performed using Fortessa (BD) and
FlowJo software.Single-Cell RNA Sequencing Analysis
The expression profiles of genes encoding APLNR and two if its
ligands were analyzed in previously published single-cell RNA
sequencing datasets. Specifically, the Aplnr expression profile in
FACS-sorted CD31+cKIThiGATA2med cells isolated from the
AGM region of E11 embryos was generated using the online
browser (https://gottgens-lab.stemcells.cam.ac.uk/DZIERZAK/)
(GEO: GSE143637) (Vink et al., 2020). The APLNR expression pro-
file in sorted CD34+ cells from the dissected AGM ventral region
from CS16 human embryos was analyzed from a GEO down-
loaded dataset (GEO: GSE1518767; sample GSM4592621) (Crosse
et al., 2020). Data were analyzed using the R package Seurat 3.2.2,
following the standard pipeline (https://www.cell.com/cell/
fulltext/S0092-8674(19)30559-8). In brief, data were normalized
using SCTransform, followed by PCA, UMAP, clustering, and
TSNE analysis using the first 20 principal components. Expres-
sion profiles in iPSC-derived hemato-endothelial cells were
obtained from our previously published dataset (EMBL EBI
Arrayexpress: E-MTAB-9295) and the plot was generated using
our browser available at lab.antonellafidanza.com (Fidanza
et al., 2020).Statistics
Data on histograms presented as average of at least three indepen-
dent experiments ± SD and difference evaluated using t test or
Prism software.Data and Code Availability
Accession numbers for the published RNA sequencing datasets
that were analyzed in this study include GEO: GSE143637 (Vink
et al., 2020), GEO: GSE1518767; sample GSM4592621 (Crosse
et al., 2020), and EMBL EBI Arrayexpress: E-MTAB-9295 (Fidanza
et al., 2020).SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2021.02.003.
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